Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Markets will remain closed on April 17, 2024 on account of Ram Navami.

Mid cap & small cap buck trend
Tue, 2 Jul 01:30 pm

Indian share markets continued to trade below the dotted line in the post-noon trading session. Majority of the sectoral indices are trading in the red with realty, IT and auto stocks being the biggest losers. However, consumer durables, pharma and metal stocks are among the few stocks trading positive.

BSE-Sensex is down 42 points and NSE-Nifty is trading 14 points down. BSE Mid Cap is trading up 0.1% whereas BSE Small Cap index is trading up by 0.3%. The rupee is trading at 59.3 to the US dollar.

Majority of the cement stocks are trading in the green with Heidelberg Cement and Prism Cement being the biggest gainers. As per a leading financial daily, Madras Cement has chalked out plans to invest Rs 3.6 bn to set up a grinding unit in Andhra Pradesh whereas Rs 550 m will be invested to increase its power generation capacity. The new unit at Vishakhapatnam is expected to go on-stream in the second quarter of FY15. The clinker required will be transported from the Jayanthipuram plant and the output will be sold in coastal Andhra Pradesh, Odisha and Chattisgarh. Prior to this, Madras Cement had set up three grinding units near fly-ash producing centres and major cement-consumption areas. As per the company, this move has helped it to reduce the cost of transportation and service its markets better. Madras Cement stock is trading 3.7% down.

Most of the Indian pharma stocks are trading in the green with Panacea Biotech and Elder Pharma leading among gainers. Glenmark Pharmaceuticals' subsidiary Glenmark Generics has received approval for generic rizatriptan benzoate orally disintegrating tablets (ODT)from USFDA (United States Food and Drug Association). The drug is generic version of Merck's Maxalt tablets. The annual sales of this drug were $263 m in FY13. Glenmark has received approval for 5mg and 10mg strengths. The company will soon commence shipment of the drug. The drug is used to cure migraine in adults and children belonging to 6-17 age group.

Even Aurobindo Pharma has received approval for rizatriptan benzonate ODT from the USFDA. Aurobindo too expects to launch the product in near term. Both the stocks, Glenmark and Aurobindo were trading up by 1.07% and 0.24% respectively.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Mid cap & small cap buck trend". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.